Analysis
How the regulatory, payments and operating environment actually behaves for businesses in this sector — and which parts of it are within an operator's control.
Regulation
On 23–24 July 2026 FDA’s Pharmacy Compounding Advisory Committee discussed fourteen salt and free-base forms of seven peptides. Staff proposed that none of them be added to the 503A Bulks List. That proposal is not a listing decision, and a committee recommendation is not one either.
12 Sept 2026 · 10 min
Regulatory
Published FDA warning letters and unapproved-drug communications in this sector cluster on intended-use claims and unapproved products — not on whether a COA percentage was high.
12 Sept 2026 · 8 min
Regulatory
FDA’s Pharmacy Compounding Advisory Committee met 23–24 July 2026 on several peptide bulk substances. Trade press reported recommendations. A recommendation is not a listing and not an approval. Identity records stay conservative until FDA publishes the primary instrument.
12 Sept 2026 · 8 min
Business & operations
A branded site inherits your claims and your documentation. If those are not ready, infrastructure accelerates the failure. PeptideFranchise is an affiliated storefront system; Vial Foundry is reference materials — do not route the wrong intent.
12 Sept 2026 · 7 min
Business & operations
Affiliate content is still your intended-use exposure. Rankings that mix HPLC percentages with discount codes are a different product from a reference file.
12 Sept 2026 · 6 min
Business & operations
For a clinic or med spa, the Therapept-relevant questions are documentation, compounding status, and claim language. This is not a treatment guide.
12 Sept 2026 · 6 min
Industry
Twelve laboratories with peptide capability stated on their own pages. Accreditation is mostly unverified against registers. Janoshik, whose PDFs circulate widely, claims none. That is the landscape — not a league table.
12 Sept 2026 · 7 min
Industry
The supplier directory mixes affiliated properties, labelled as such, with independent records sourced to a company's own pages. That mix is a disclosed limitation, not a market map.
12 Sept 2026 · 5 min
Industry
In circulating research-peptide certificates, HPLC area percent is common; observed mass is less so; net peptide content, endotoxin and sterility are often absent. Treat that as a documentation pattern, not a quality ranking of shops.
12 Sept 2026 · 6 min
Business & operations
The hard parts of this business are not the ones most people plan for. Sourcing, documentation, payments and claim discipline determine whether an operation survives — the storefront is the easy half.
3 Sept 2026 · 11 min
Business & operations
Payment access is the most common single point of failure for peptide merchants. The underwriting logic is not arbitrary, and understanding what it is actually measuring makes most of the outcome controllable.
3 Sept 2026 · 8 min
Intelligence pieces are published when there is something specific and sourceable to say. Therapept does not maintain a payment processor directory: policies in this category change often enough that a published list would be misleading within months, and a stale recommendation there is worse than none.
